ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1893

Statin Exposure Moderates the Effects of Chronic Inflammation on Coronary Atherosclerosis Progression and Cardiovascular Events in Rheumatoid Arthritis

George Karpouzas1, Sarah Ormseth 1, Elizabeth Hernandez 2 and Matthew Budoff 1, 1Harbor-UCLA Medical Center and Los Angeles Biomedical Institute, Torrance, CA, 2Harbor-UCLA and Los Angeles Biomedical Institute, Torrance, CA

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Rheumatoid arthritis (RA), statins and cardiovascular disease

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 11, 2019

Session Title: 4M117: RA – Treatments III: Cardiovascular Disease & Readmissions (1890–1895)

Session Type: ACR Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: Chronic inflammation yields higher risk of cardiovascular events (CVE) in patients with rheumatoid arthritis (RA). We recently reported that occult atherosclerosis burden on coronary computed tomography angiography (CCTA) predicted CVE in RA beyond cardiac risk factors or scores. We further showed that that higher cumulative inflammation independently predicted coronary plaque progression. We here explored whether statin exposure impacted plaque progression or incident CVE in RA; we further evaluated potential interactions of statin treatment with cumulative inflammation on both outcomes.

Methods: One hundred-fifty RA patients underwent a baseline CCTA and followed thereafter; 101 had a repeat scan within 83±3.6 months. Coronary artery calcium (CAC) was reported as Agatston score. Segment involvement score (SIS) reported numbers of coronary segments with plaque; segment stenosis score (SSS) reflected the cumulative plaque stenosis. Plaque composition was defined as non-calcified (NCP), mixed or calcified. Cox proportional hazards regression models with time-varying covariates evaluated predictors of CVE. Negative binomial regression was used to assess count outcomes and a generalized linear model with a Tweedie (Poisson-Gamma) error distribution for CAC change.

Results: Longer statin exposure independently inhibited NCP progression [OR=0.72 (0.57-0.90), p< 0.01]. An interaction between cumulative inflammation and duration of statin exposure on total SIS increase (p=0.017) as well as CAC increase (p=0.006) was observed independently of age, dyslipidemia, total prednisone and methotrexate dose and bDMARD duration (Figure 1A and B respectively); higher time-averaged CRP yielded significant plaque progression in patients not on statin [RR=1.48 (1.05-2.09), p=0.025] or those receiving statins< 50% of the study period [RR=1.31 (1.01-1.69), p=0.040]. In contrast, in subjects with statin exposure >50% of study time, such risk was not observed [RR=1.07 (0.93-1.22), p=0.35]. Similarly for CAC, higher time-averaged CRP yielded greater progression risk in statin unexposed patients [OR=2.33 (1.29-4.22), p=0.005]; in contrast, any statin exposure mitigated that risk [OR=1.17 (0.81-1.68), p=0.41 for exposure< 50% and OR=0.96 (0.44-2.17), p=0.98 for exposure >50%]. Sixteen RA patients incurred 19 CVEs. Higher cumulative inflammation yielded significantly higher CVE risk in patients not receiving statins vs. those who do [HR=1.34 (1.11-1.63), p=0.003 and 0.39 (0.05-2.91), p=0.36 respectively, p-interaction=0.05, Figure 1C].

Conclusion: Statin exposure moderates the effect of cumulative inflammation on coronary atherosclerosis progression and CVE risk in RA. The atheroprotective effect of statins may highlight potential local anti-inflammatory attributes at the plaque level independently of systemic inflammation.


Disclosure: G. Karpouzas, Bristol Meyer Squibb, 8, bristol Meyer Squibb, 8, Bristol-Meyer-Squibb, 8, Pfizer, 2, 9, pfizer, 2, Sanofi, 5, 8; S. Ormseth, None; E. Hernandez, None; M. Budoff, None.

To cite this abstract in AMA style:

Karpouzas G, Ormseth S, Hernandez E, Budoff M. Statin Exposure Moderates the Effects of Chronic Inflammation on Coronary Atherosclerosis Progression and Cardiovascular Events in Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/statin-exposure-moderates-the-effects-of-chronic-inflammation-on-coronary-atherosclerosis-progression-and-cardiovascular-events-in-rheumatoid-arthritis/. Accessed January 30, 2023.
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/statin-exposure-moderates-the-effects-of-chronic-inflammation-on-coronary-atherosclerosis-progression-and-cardiovascular-events-in-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences